Research map: SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy

Back to the article

Papers in this map

  1. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions · Xiaojun Lance Lian · 2012 · 1870 citations · Cited by this paper
  2. Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling · 2026 · Related
  3. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling · Xiaojun Lance Lian · 2012 · 1797 citations · Cited by this paper
  4. Mechanisms and functions of the TRIM protein family in digestive system cancers · 2026 · Related
  5. Chemically defined conditions for human iPSC derivation and culture · Guokai Chen · 2011 · 1525 citations · Cited by this paper
  6. Deep N-glycoproteomic profiling of FFPE tissues enables precise diagnosis of primary liver cancer from metastatic liver cancer · 2026 · Related
  7. Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy · Ning Sun · 2012 · 706 citations · Cited by this paper
  8. Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity · 2026 · Related
  9. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits · Antonius Baartscheer · 2016 · 671 citations · Cited by this paper
  10. Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting · 2026 · Related
  11. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy · John Travis Hinson · 2015 · 661 citations · Cited by this paper
  12. Methionine addiction in oral squamous cell carcinoma: a metabolic vulnerability targeted by engineered bacteria · 2026 · Related
  13. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation · Laween Uthman · 2017 · 616 citations · Cited by this paper
  14. Targeting the IL-17C-M2 macrophage axis ameliorates fibrosis in endometriosis through MAPK/ERK signaling · 2026 · Related
  15. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart · Chenguang Li · 2019 · 600 citations · Cited by this paper
  16. Precision hyperbaric oxygen therapy: a biomarker-driven framework · 2026 · Related
  17. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes · Mark Colquhoun Petrie · 2020 · 548 citations · Cited by this paper
  18. Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy · 2025 · Related
  19. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi) · Jessie Gu · 2009 · 509 citations · Cited by this paper
  20. Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class · 2025 · Related
  21. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status · Stefan D. Anker · 2020 · 359 citations · Cited by this paper
  22. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation · Detmar Kolijn · 2020 · 334 citations · Cited by this paper
  23. Heart failure drug treatment: the fantastic four · Johann K Bauersachs · 2020 · 296 citations · Cited by this paper
  24. Empagliflozin Directly Improves Diastolic Function in Human Heart Failure · Steffen Pabel · 2018 · 227 citations · Cited by this paper
  25. The physiological role of cardiac cytoskeleton and its alterations in heart failure · Vasco Sequeira · 2013 · 195 citations · Cited by this paper
  26. Leptin Attenuates Cardiac Contraction in Rat Ventricular Myocytes · Marvie W. Nickola · 2000 · 183 citations · Cited by this paper
  27. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence · Khawaja Muhammad Talha · 2023 · 183 citations · Cited by this paper
  28. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes · Nadjib Hammoudi · 2017 · 150 citations · Cited by this paper
  29. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due toTTNmutations · Andrey Fomin · 2021 · 138 citations · Cited by this paper
  30. Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure · Xuan Li · 2021 · 119 citations · Cited by this paper
  31. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long‐term treatment · Calle Bengtsson · 1975 · 114 citations · Cited by this paper
  32. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects · Giuseppe Palmiero · 2021 · 113 citations · Cited by this paper
  33. Cardiac Disorders and Pathophysiology of Sarcomeric Proteins · Jolanda van der Velden · 2018 · 111 citations · Cited by this paper
  34. Mechano-regulated Tenascin-C orchestrates muscle repair · Martin Flück · 2008 · 104 citations · Cited by this paper
  35. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system · Antje Ebert · 2014 · 103 citations · Cited by this paper
  36. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress · Weijuan Cai · 2023 · 99 citations · Cited by this paper
  37. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia/reperfusion injury · Li Zhao · 2019 · 85 citations · Cited by this paper
  38. Proteasome-Dependent Regulation of Distinct Metabolic States During Long-Term Culture of Human iPSC-Derived Cardiomyocytes · Antje Ebert · 2019 · 80 citations · Cited by this paper
  39. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy · Na Li · 2020 · 68 citations · Cited by this paper

Source: OpenAlex (CC0)